{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:27:01Z","timestamp":1789723621783,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370657"],"award-info":[{"award-number":["81370657"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770166"],"award-info":[{"award-number":["81770166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470328"],"award-info":[{"award-number":["81470328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81720108002"],"award-info":[{"award-number":["81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00432-017-2568-2","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T10:43:33Z","timestamp":1514976213000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"144","author":[{"given":"Wen-Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-7477","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"2568_CR1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198\u2013206","journal-title":"Cancer"},{"key":"2568_CR2","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252\u20137259","journal-title":"Clin Cancer Res"},{"key":"2568_CR3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.leukres.2008.02.005","volume":"32","author":"L Chen","year":"2008","unstructured":"Chen L, Zhang Y, Zheng W et al (2008) Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1491\u20131498","journal-title":"Leuk Res"},{"key":"2568_CR4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","volume":"29","author":"CI Chen","year":"2011","unstructured":"Chen CI, Bergsagel PL, Paul H et al (2011) Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29:1175\u20131181","journal-title":"J Clin Oncol"},{"key":"2568_CR5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03521.x","volume":"135","author":"RT Costello","year":"2012","unstructured":"Costello RT, Knoblauch B, Sanchez C et al (2012) Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology 135:151\u2013157","journal-title":"Immunology"},{"key":"2568_CR6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","volume":"66","author":"RS Cvetkovi\u0107","year":"2006","unstructured":"Cvetkovi\u0107 RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs 66:791\u2013820","journal-title":"Drugs"},{"issue":"Suppl 5","key":"2568_CR7","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E et al (2015) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v78\u201384","journal-title":"Ann Oncol"},{"key":"2568_CR8","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","volume":"111","author":"A Ferrajoli","year":"2008","unstructured":"Ferrajoli A, Lee BN, Schlette EJ et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291\u20135297","journal-title":"Blood"},{"key":"2568_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","volume":"98","author":"R Foa","year":"2013","unstructured":"Foa R, Del Giudice I, Guarini A et al (2013) Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98:675\u2013685","journal-title":"Haematologica"},{"key":"2568_CR10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2008","unstructured":"Galustian C, Meyer B, Labarthe M-C et al (2008) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033\u20131045","journal-title":"Cancer Immunol Immunother"},{"key":"2568_CR11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"128","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192\u2013203","journal-title":"Br J Haematol"},{"key":"2568_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/CJI.0b013e31820e1b0d","volume":"34","author":"B Huang","year":"2011","unstructured":"Huang B, Sikorski R, Sampath P, Thorne SH (2011) Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 34:289\u2013296","journal-title":"J Immunother"},{"key":"2568_CR13","doi-asserted-by":"crossref","first-page":"e108326","DOI":"10.1371\/journal.pone.0108326","volume":"9","author":"L Huergo-Zapico","year":"2014","unstructured":"Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP et al (2014) Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS ONE 9:e108326","journal-title":"PLoS ONE"},{"key":"2568_CR14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington ND, Vosshenrich CAJ, Di Santo JP (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7:703\u2013714","journal-title":"Nat Rev Immunol"},{"key":"2568_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","volume":"63","author":"NE Kay","year":"1984","unstructured":"Kay NE, Zarling JM (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63:305\u2013309","journal-title":"Blood"},{"key":"2568_CR16","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.4049\/jimmunol.1300187","volume":"191","author":"E Laprevotte","year":"2013","unstructured":"Laprevotte E, Voisin G, Ysebaert L et al (2013) Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 191:3634\u20133640","journal-title":"J Immunol"},{"key":"2568_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2010.01.011","volume":"392","author":"L Liu","year":"2010","unstructured":"Liu L, Chen B, Qin S et al (2010) A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 392:190\u2013195","journal-title":"Biochem Biophys Res Commun"},{"key":"2568_CR18","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","volume":"6","author":"AW MacFarlane","year":"2017","unstructured":"MacFarlane AW, Jillab M, Smith MR et al (2017) NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology 6:e1330235","journal-title":"Oncoimmunology"},{"key":"2568_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"Z-Q Ning","year":"2011","unstructured":"Ning Z-Q, Li Z-B, Newman MJ et al (2011) Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69:901\u2013909","journal-title":"Cancer Chemother Pharmacol"},{"key":"2568_CR20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood-2004-08-3335","volume":"105","author":"H N\u00fcckel","year":"2005","unstructured":"N\u00fcckel H, Rebmann V, D\u00fcrig J et al (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105:1694\u20131698","journal-title":"Blood"},{"key":"2568_CR21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07070.x","volume":"141","author":"S Palmer","year":"2008","unstructured":"Palmer S, Hanson CA, Zent CS et al (2008) Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 141:607\u2013614","journal-title":"Br J Haematol"},{"issue":"2","key":"2568_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219\u2013234","journal-title":"Blood"},{"key":"2568_CR23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3324\/haematol.2013.095281","volume":"99","author":"R Rizzo","year":"2014","unstructured":"Rizzo R, Audrito V, Vacca P et al (2014) HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 bp (rs66554220) polymorphism. Haematologica 99:888\u2013896","journal-title":"Haematologica"},{"key":"2568_CR24","unstructured":"Romagnani C (2013) Signatures of human NK cell development and terminal differentiation. Front Immunol 4:1\u20136"},{"key":"2568_CR25","first-page":"1166","volume":"56","author":"T Sarah","year":"2015","unstructured":"Sarah T (2015) XVI international workshop on chronic lymphocytic leukemia 2015 6\u20139 September 2015 Sydney, Australia. Leuk Lymphoma 56:1\u2013166","journal-title":"Leuk Lymphoma"},{"key":"2568_CR26","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766\u20131771","journal-title":"Ann Oncol"},{"key":"2568_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M et al (2013) Innate lymphoid cells\u2013a proposal for uniform nomenclature. Nat Rev Immunol 13:145\u2013149","journal-title":"Nat Rev Immunol"},{"key":"2568_CR28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10875-011-9624-5","volume":"32","author":"C Veuillen","year":"2012","unstructured":"Veuillen C, Aurran-Schleinitz T, Castellano R et al (2012) Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 32:632\u2013646","journal-title":"J Clin Immunol"},{"key":"2568_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115\u2013123","journal-title":"Semin Hematol"},{"key":"2568_CR30","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.humimm.2013.08.277","volume":"74","author":"P W\u0142asiuk","year":"2013","unstructured":"W\u0142asiuk P, Tomczak W, Zaj\u0105c M et al (2013) Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. Hum Immunol 74:1592\u20131597","journal-title":"Hum Immunol"},{"key":"2568_CR31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2007.10.009","volume":"32","author":"W Xu","year":"2008","unstructured":"Xu W, Li J-Y, Wu Y-J et al (2008) Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1071\u20131077","journal-title":"Leuk Res"},{"key":"2568_CR32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.leukres.2008.06.026","volume":"33","author":"W Xu","year":"2009","unstructured":"Xu W, Li J-Y, Wu Y-J et al (2009) CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 33:237\u2013243","journal-title":"Leuk Res"},{"key":"2568_CR33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2013.07.005","volume":"34","author":"J Yu","year":"2013","unstructured":"Yu J, Freud AG, Caligiuri MA (2013) Location and cellular stages of natural killer cell development. Trends Immunol 34:573\u2013582","journal-title":"Trends Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2568-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T04:47:35Z","timestamp":1603601255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2568-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2568"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2568-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}